Rare diseases
Investigational molecules
Locations
11 Boulevard Lacordaire, Hopital Victor Provo, 59100 Roubaix, France
Centre Hospitalier De Roubaix in Roubaix, France specialises in clinical trials of conditions such as Acute myeloid leukaemia, Crohn's disease, Acute lymphocytic leukaemia, Asthma, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in Peripheral T-cell lymphoma (PTCL), focusing on innovative treatment strategies to improve patient outcomes. The center's research is particularly centered on the efficacy of autologous stem cell transplantation (ASCT) in prolonging progression-free survival for patients who achieve a complete response after induction chemotherapy.
Through these studies, the center aims to refine therapeutic approaches and establish new standards of care for PTCL patients.
In the realm of Alzheimer's disease, the center is pioneering research into cognitive therapies, with a particular focus on the potential benefits of caffeine treatment. This research evaluates the impact of caffeine on cognitive decline in early to moderate stages of Alzheimer's, offering new insights into non-traditional therapeutic options.
The center's work in this area is crucial for developing alternative treatment pathways that could enhance the quality of life for Alzheimer's patients.
The center is advancing the treatment of Mycobacterium avium complex (MAC) lung disease through comparative studies of antibiotic regimens. The research focuses on the non-inferiority of azithromycin compared to clarithromycin, providing clinicians with evidence-based options for effective treatment.
This research is instrumental in guiding clinical decisions and optimizing treatment protocols for MAC infections.
In the field of severe allergic asthma, the center is exploring the management of asthma through the strategic withdrawal of omalizumab. The research aims to demonstrate the non-inferiority of discontinuing omalizumab in patients who have achieved asthma control, potentially reducing long-term medication dependency.
This study is pivotal in shaping future asthma management strategies, emphasizing patient-centered care.
The center is conducting significant research in Crohn's Disease, focusing on the comparative efficacy of azathioprine and methotrexate when used in combination with adalimumab. This research aims to determine the optimal combination therapy for achieving endoscopic response in Crohn's patients.
The findings from this research are expected to enhance therapeutic strategies and improve patient outcomes in Crohn's Disease management.
Clinical trials currently enrolling participants at this site.
One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease
FranceStudy of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes
FranceStudy on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms
FranceStudy Comparing Azathioprine and Methotrexate with Adalimumab for Patients with Crohn's Disease
FranceStudy on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment
FranceStudy Comparing Clarithromycin and Azithromycin for Treating Mycobacterium Avium Complex Lung Infections in Adults
FranceStudy on the Effects of Caffeine on Cognitive Function in Patients with Early to Moderate Alzheimer's Disease
FranceStudy Comparing CPX-351 and Chemotherapy for Patients with New Intermediate or High-Risk Acute Myeloid Leukemia
FranceStudy on Blood Pressure Management with Amiloride Hydrochloride, Indapamide, and Furosemide for Patients with Uncontrolled Hypertension and Chronic Kidney Disease
FranceStudy on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination
FranceStudy on Landiolol Hydrochloride and Sodium Chloride for Reducing Mortality in Patients with Septic Shock and High Heart Rate
FranceStudy on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
FranceMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
